KR100783835B1 - 면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 - Google Patents
면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 Download PDFInfo
- Publication number
- KR100783835B1 KR100783835B1 KR1020067009783A KR20067009783A KR100783835B1 KR 100783835 B1 KR100783835 B1 KR 100783835B1 KR 1020067009783 A KR1020067009783 A KR 1020067009783A KR 20067009783 A KR20067009783 A KR 20067009783A KR 100783835 B1 KR100783835 B1 KR 100783835B1
- Authority
- KR
- South Korea
- Prior art keywords
- thiazolidine
- ylidene
- benz
- hydroxy
- ethoxy
- Prior art date
Links
- 0 CCC(C)CC=C(*CCCC(CC1)=C)[C@@]1c1ccccc1 Chemical compound CCC(C)CC=C(*CCCC(CC1)=C)[C@@]1c1ccccc1 0.000 description 3
- CNSYONBUPZKTIO-PXXKEIBKSA-N CC(C)/N=C(/C(CCC1=O)c2ccccc2)\S/C1=C\c(cc1)cc(Cl)c1OCC(CO)OC Chemical compound CC(C)/N=C(/C(CCC1=O)c2ccccc2)\S/C1=C\c(cc1)cc(Cl)c1OCC(CO)OC CNSYONBUPZKTIO-PXXKEIBKSA-N 0.000 description 1
- UGWSMMPPPLEHMD-NSOYXMAOSA-N CC(C)/N=C(/N(Cc1ccccc1)C1=O)\S/C1=C\c(cc1)ccc1OCC(CO)OC Chemical compound CC(C)/N=C(/N(Cc1ccccc1)C1=O)\S/C1=C\c(cc1)ccc1OCC(CO)OC UGWSMMPPPLEHMD-NSOYXMAOSA-N 0.000 description 1
- KNHIZVIGOYBJRH-BMRADRMJSA-N CCCC/N=C(\CSCC1=O)/N1c1cccc(C)c1C Chemical compound CCCC/N=C(\CSCC1=O)/N1c1cccc(C)c1C KNHIZVIGOYBJRH-BMRADRMJSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
Abstract
Description
화합물 | 림프구 수치 [%] |
4 | -32 |
7 | -67 |
24 | -54 |
42 | -23 |
46 | -37 |
75 | -47 |
76 | -58 |
77 | -55 |
84 | -68 |
85 | -63 |
86 | -30* |
91 | -35 |
95 | -53 |
100 | -53 |
103 | -47 |
110 | -30 |
130 | -26 |
Claims (46)
- 활성 성분으로 화학식(I)의 적어도 한가지 티아졸리딘-4-원 유도체, 형태 이성질체, 광학적으로 순수한 거울상이성질체, 라셈체와 같은 거울상이성질체의 혼합물, 부분입체이성질체, 부분입체이성질체의 혼합물, 부분입체이성질성 라셈체, 부분입체이성질성 라셈체의 혼합물, 메소 형태(meso-form), 제약학적으로 허용가능한 염을 함유하고, 이식된 장기 또는 조직의 거부반응; 이식에 의해 유발된 이식편-숙주 질환; 류마티스 관절염, 다발성 경화증, 중증근무력증을 포함하는 자가 면역 증후군; 꽃가루 알레르기; 타입 I 당뇨병, 건선 예방, 크론 질환, 류마티즘열, 감염후 사구체신염을 포함하는 감염후 자가면역 질환, 암종의 전이에서 선택되는 질병 치료용 약학 조성물:화학식(I)R1은 저급 알킬; 저급 알케닐; 사이클로알킬; 5,6,7,8-테트라하이드로나프트-1-일; 5,6,7,8-테트라하이드로나프트-2-일; 페닐기; 저급 알킬, 할로겐, 저급 알콕시로 독립적으로 단일-, 이중- 또는 삼중치환된 페닐기, 또는 -CF3이고;R2는 저급 알킬; 알릴; 사이클로프로필; 사이클로부틸; 사이클로펜틸; 모노- 또는 디-저급 알킬아미노이고;R3은 -NR5R6; -O-CR7R8-CR9R10-(CR11R12)n-O-R13이고;R4는 수소; 하이드록시; 저급 알콕시; 저급 알킬; 할로겐이고; 또는 R3과 R4가 서로 결합하여, 선택적으로 하이드록시 메틸기로 더욱 치환되는 메틸렌디옥시 또는 에틸렌디옥시 고리를 형성하고;R5와 R6은 각각 독립적으로 저급 알킬이고;R7은 수소, 저급 알킬, 또는 하이드록시메틸이고;R8, R9, R11, R12는 각각 독립적으로 수소 또는 메틸이고;R10은 수소 또는 저급 알킬이고; n이 정수 1인 경우에, R10은 저급 알콕시, 하이드록시, -NH2, -NHR5 또는 -NR5R6이고;R13은 수소; 저급 알킬; 하이드록시카르보닐-저급 알킬; 1-글리세릴 또는 2-글리세릴이고;n은 정수 0 또는 1이다.이때, "저급(lower) 알킬", "저급(lower) 알콕시", "모노(mono)- 또는 디(di) 저급(lower) 알킬아미노", "저급(lower) 알레닐", "사이클로알킬"은 다음과 같이 정의한다:"저급 알킬"은 1 내지 7개 탄소 원자를 가지는 포화된 직쇄 또는 분지쇄 기를 말하며,"저급 알콕시"는 R-O기로 이때 R은 저급 알킬이 되며,"모노- 또는 디 저급 알킬아미노"는 R'-NH 또는 R'-NR''기로써, R' 및 R''는 각각 저급 알킬이 되며,"저급 알케닐"은 올레핀 결합이 있는 3 내지 7개 탄소 원자로 된 직쇄 또는 분지쇄 기가 되며,"사이클로알킬"은 3 내지 7개 탄소원자를 가진 포화된 고리 탄화수소 고리를 말한다.
- 제 1항에 있어서, 티아졸리딘-4-원 유도체는 화학식(I)에 따른 (Z,Z)-이성질체인 것을 특징으로 하는 제약학적 조성물.
- 삭제
- 화학식(II)의 신규한 티아졸리딘-4-원 유도체, 형태 이성질체, 광학적으로 순수한 거울상이성질체, 라셈체와 같은 거울상이성질체의 혼합물, 부분입체이성질체, 부분입체이성질체의 혼합물, 부분입체이성질성 라셈체, 부분입체이성질성 라셈체의 혼합물, 메소 형태(meso-form), 제약학적으로 허용가능한 염:화학식(II)R14는 저급 알킬, 저급 알케닐; 사이클로알킬; 5,6,7,8-테트라하이드로나프트-1-일; 5,6,7,8-테트라하이드로나프트-2-일; 페닐기; 저급 알킬, 할로겐, 저급 알콕시로 독립적으로 단일-, 이중- 또는 삼중치환된 페닐기, 또는 -CF3이고;R15는 저급 알킬; 알릴; 사이클로프로필; 사이클로부틸; 사이클로펜틸; 모노- 또는 디-저급 알킬아미노이고;R16은 수소; 하이드록시; 저급 알콕시; 저급 알킬 또는 할로겐이고;R17은 수소, 저급 알킬, 또는 하이드록시메틸이고;R18, R19, R21, R22는 각각 독립적으로 수소 또는 메틸이고;R20은 수소 또는 저급 알킬이고; m이 정수 1인 경우에, R20은 저급 알콕시, 하이드록시 또는 -NH2이고;R23은 수소; 저급 알킬; 하이드록시카르보닐-저급 알킬; 1-글리세릴 또는 2-글리세릴이고;m은 정수 0 또는 1이고;이때, "저급(lower) 알킬", "저급(lower) 알콕시", "모노(mono)- 또는 디(di) 저급(lower) 알킬아미노", "저급(lower) 알레닐", "사이클로알킬"은 다음과 같이 정의한다:"저급 알킬"은 1 내지 7개 탄소 원자를 가지는 포화된 직쇄 또는 분지쇄 기를 말하며,"저급 알콕시"는 R-O기로 이때 R은 저급 알킬이 되며,"모노- 또는 디 저급 알킬아미노"는 R'-NH 또는 R'-NR''기로써, R' 및 R''는 각각 저급 알킬이 되며,"저급 알케닐"은 올레핀 결합이 있는 3 내지 7개 탄소 원자로 된 직쇄 또는 분지쇄 기가 되며,"사이클로알킬"은 3 내지 7개 탄소원자를 가진 포화된 고리 탄화수소 고리를 말한다.
- 제 4항에 있어서, 화학식(II)에 따른 티아졸리딘-4-원 유도체는 (Z,Z)-이성질체인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R14는 치환되지 않거나, 또는 단일- 또는 이중치환된 페닐기인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 제5항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R15는 저급 알킬인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R16은 할로겐 또는 메틸인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, m은 정수 0이고, R17, R18, R19, R20은 수소인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, m은 정수 1이고, R17, R18, R19, R21, R22는 수소이고, R20은 하이드록시인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R23은 수소인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, m은 정수 0이고, R17, R18, R19, R20, R23은 수소인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, m은 정수 1이고, R17, R18, R19, R21, R22, R23은 수소이고, R20은 하이드록시인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기이고, R15는 저급 알킬인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기이고, m은 정수 0이고, R17, R18, R19, R20, R23은 수소인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기이고, m은 정수 1이고, R17, R18, R19, R21, R22, R23은 수소이고, R20은 하이드록시인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기이고, R15는 저급 알킬이고, R16은 메틸 또는 할로겐이고, m은 정수 0이고, R17, R18, R19, R20, R23은 각각 수소인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항 또는 5항에 있어서, R14는 치환되지 않거나, 또는 메틸 또는 할로겐으로 단일- 또는 이중치환된 페닐기이고; R15는 저급 알킬이고, R16은 메틸 또는 할로겐이고, m은 정수 1이고, R17, R18, R19, R21, R22, R23은 수소이고, R20은 하이드록시인 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 제 4항에 있어서, 아래에서 선택되는 것을 특징으로 하는 티아졸리딘-4-원 유도체:5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,2-[4-(2-([Z]-이소프로필이미노)-4-옥소-3-페닐-티아졸리딘-5-[Z]-일리덴메틸)-페녹시]-에톡시-아세트산,5-4-[2-(2,3-디하이드록시-프로폭시)-에톡시]-벤즈[Z]일리덴-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[3-플루오르-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메톡시-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[4-(3-하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-4-[2-(2,3-디하이드록시-프로폭시)-에톡시]-벤즈[Z]일리덴-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메톡시-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[4-(3-하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-m-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-m-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-m-톨릴-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-p-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-p-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-p-톨릴-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-4-[2-(2,3-디하이드록시-프로폭시)-에톡시]-벤즈[Z]일리덴-3-(2,3-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[3-플루오르-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-3-메톡시-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2,4-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-(2,3-디하이드로-벤조[1,4]디옥신-6-[Z]-일메틸렌)-3-(2,6-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2,6-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-(2-클로로-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2-클로로-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2-클로로-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-(2-메톡시-페닐)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-(2-메톡시-페닐)-티아졸리딘-4-원,5-(2,3-디하이드로-벤조[1,4]디옥신-6-[Z]-일메틸렌)-2-([Z]-이소프로필이미노)-3-메톡시-페닐)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-(4-메톡시-페닐)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-(4-메톡시-페닐)-티아졸리딘-4-원,3-알릴-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-알릴-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,3-알릴-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[4-(3-하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,(R)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,(S)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-4-[2-(2,3-디하이드록시-프로폭시)-에톡시]-벤즈[Z]일리덴-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-3-메톡시-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,2-([Z]-tert-부틸이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,2-(디메틸-하이드라조노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-(디메틸-하이드라조노)-3-페닐-티아졸리딘-4-원,2-([Z]-에틸이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-에틸이미노)-3-페닐-티아졸리딘-4-원,2-([Z]-에틸이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-에틸이미노)-3-o-톨릴-티아졸리딘-4-원,3-(2,3-디메틸-페닐)-2-([Z]-에틸이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-에틸이미노)-티아졸리딘-4-원,2-([Z]-부틸이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,2-([Z]-부틸이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,2-([Z]-부틸이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-o-톨릴-티아졸리딘-4-원,2-([Z]-부틸이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-o-톨릴-티아졸리딘-4-원,2-([Z]-부틸이미노)-3-(2,3-디메틸-페닐)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-티아졸리딘-4-원,2-([Z]-부틸이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-티아졸리딘-4-원,2-([Z]-sec-부틸이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,2-([Z]-사이클로프로필이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,3-사이클로헥실-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-사이클로헥실-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-이소프로필-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-이소프로필-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-이소프로필-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,2-([Z]-알릴이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,2-([Z]-알릴이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,3-알릴-2-([Z]-알릴이미노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-티아졸리딘-4-원,3-알릴-2-([Z]-알릴이미노)-5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-메틸이미노)-3-페닐-티아졸리딘-4-원, 그리고5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-메틸이미노)-티아졸리딘-4-원,
- 제 4항에 있어서, 아래에서 선택되는 것을 특징으로 하는 티아졸리딘-4-원 유도체:5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-이소프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-이소프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[4-(2-하이드록시-에톡시)-3-메틸-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-페닐-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,(R)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,(S)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-2-([Z]-프로필이미노)-3-o-톨릴-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-프로필이미노)-티아졸리딘-4-원,2-(디메틸-하이드라조노)-5-[4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-2-([Z]-에틸이미노)-3-페닐-티아졸리딘-4-원,5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-(2,3-디메틸-페닐)-2-([Z]-에틸이미노)-티아졸리딘-4-원, 그리고5-[3-클로로-4-(2-하이드록시-에톡시)-벤즈[Z]일리덴]-3-이소프로필-2-([Z]-이소프로필이미노)-티아졸리딘-4-원.
- 제 4항에 있어서, 약물로서 사용되는 것을 특징으로 하는 티아졸리딘-4-원 유도체.
- 삭제
- 활성 성분으로 제 4항에 따른 화학식(II)의 적어도 한가지 화합물으로 하고불활성 담체 물질을 함유하는 이식된 장기 또는 조직의 거부반응; 이식에 의해 유발된 이식편-숙주 질환; 류마티스 관절염, 다발성 경화증, 중증근무력증을 포함하는 자가 면역 증후군; 꽃가루 알레르기; 타입 I 당뇨병, 건선 예방, 크론 질환, 류마티즘열, 감염후 사구체신염을 포함하는 감염후 자가면역 질환, 암종의 전이등에서 선택된 질환 치료용 약학 조성물.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP03/13072 | 2003-11-21 | ||
EP0313072 | 2003-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060117328A KR20060117328A (ko) | 2006-11-16 |
KR100783835B1 true KR100783835B1 (ko) | 2007-12-10 |
Family
ID=34639216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067009783A KR100783835B1 (ko) | 2003-11-21 | 2004-11-16 | 면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 |
Country Status (26)
Country | Link |
---|---|
US (8) | USRE43728E1 (ko) |
EP (2) | EP2295418A1 (ko) |
JP (2) | JP4061332B2 (ko) |
KR (1) | KR100783835B1 (ko) |
CN (1) | CN100567275C (ko) |
AR (1) | AR047128A1 (ko) |
AT (1) | ATE483698T1 (ko) |
AU (1) | AU2004295047B2 (ko) |
BR (1) | BRPI0416752B8 (ko) |
CA (1) | CA2545582C (ko) |
CY (1) | CY1111087T1 (ko) |
DE (1) | DE602004029493D1 (ko) |
DK (1) | DK1689726T3 (ko) |
ES (1) | ES2352555T3 (ko) |
HR (1) | HRP20100714T1 (ko) |
IL (1) | IL175758A (ko) |
MY (1) | MY145074A (ko) |
NO (1) | NO336734B1 (ko) |
NZ (1) | NZ547962A (ko) |
PL (1) | PL1689726T3 (ko) |
PT (1) | PT1689726E (ko) |
RU (1) | RU2379299C2 (ko) |
SI (1) | SI1689726T1 (ko) |
TW (1) | TWI323659B (ko) |
WO (1) | WO2005054215A1 (ko) |
ZA (1) | ZA200605077B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101409597B1 (ko) * | 2008-10-20 | 2014-06-20 | 액테리온 파마슈티칼 리미티드 | (r)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[z]일리덴]-2-([z]-프로필이미노)-3-0-톨릴-티아졸리딘-4-온의 결정 형태 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
RU2379299C2 (ru) | 2003-11-21 | 2010-01-20 | Актелион Фармасьютиклз Лтд | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов |
JP2007523957A (ja) * | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
CA2576388A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
EP2298308B1 (en) * | 2005-11-14 | 2013-01-16 | University Of Southern California | Integrin-binding small molecules |
JP4182986B2 (ja) * | 2006-04-19 | 2008-11-19 | トヨタ自動車株式会社 | 半導体装置とその製造方法 |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
EP2489662B1 (en) | 2006-11-23 | 2014-08-06 | Actelion Pharmaceuticals Ltd. | Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives |
BRPI0909625B1 (pt) * | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
EP2598126A2 (en) * | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
RS60408B1 (sr) | 2012-08-17 | 2020-07-31 | Actelion Pharmaceuticals Ltd | Postupak za pripremanje (2z,5z)-5-(3-hloro-4-((r)-2,3-dihidroksipropoksi)benziliden)-2-(propilimino)-3-(o-tolil)tiazolidin-4-ona i međujedinjenja upotrebljena u pomenutom postupku |
WO2014175287A1 (ja) | 2013-04-26 | 2014-10-30 | 国立大学法人 京都大学 | 脳動脈瘤の形成および/または増大の抑制若しくは縮小用医薬組成物 |
EP2862574A1 (en) | 2013-10-15 | 2015-04-22 | Sanofi | {4-[5-(3-chloro-phenoxy)-oxazolo[5,4 d]pyrimidin-2-yl]-2,6-dimethyl-phenoxy}-acetic acid for use in the prevention or treatment of acute kidney injury |
CA2950354C (en) * | 2014-05-28 | 2023-10-03 | Universitat Bern | Thiazolidinone compounds and their use in the treatment of psychiatric or neurological disorders |
EP2952188A1 (en) * | 2014-06-03 | 2015-12-09 | Universität Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
US10300048B2 (en) | 2014-05-28 | 2019-05-28 | Universitat Bern | Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation |
EP3256125B1 (en) | 2014-12-11 | 2022-01-26 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
CA3009713A1 (en) | 2015-12-25 | 2017-06-29 | Crystal Pharmatech Co., Ltd. | Crystalline forms of ponesimod and preparation method thereof |
JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
EP3684358A4 (en) | 2017-09-19 | 2021-01-13 | Teva Pharmaceuticals International GmbH | NEW CRYSTALLINE POLYMORPHIC SHAPE OF PONESIMOD |
TWI647229B (zh) * | 2017-11-14 | 2019-01-11 | 國立暨南國際大學 | Method for synthesizing 3,4-hydroisoquinoline thiazolidine |
US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
AU2020372647A1 (en) | 2019-10-31 | 2022-06-16 | Idorsia Pharmaceuticals Ltd | Combination of a CXCR7 antagonist with an S1P1 receptor modulator |
US20230055568A1 (en) | 2020-02-06 | 2023-02-23 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for myalgic encephalomyelitis/chronic fatigue syndrome |
WO2023022896A1 (en) | 2021-08-17 | 2023-02-23 | Teva Czech Industries S.R.O | Polymorphs of ponesimod |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
WO2023152691A1 (en) * | 2022-02-10 | 2023-08-17 | Metrochem Api Pvt Ltd | Process for the preparation of ponesimod and its intermediates thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1219612A1 (en) * | 1999-09-14 | 2002-07-03 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3077402A (en) | 1954-12-06 | 1963-02-12 | Polaroid Corp | Photographic color processes, products, and compositions |
NL270002A (ko) | 1960-10-08 | |||
OA03835A (fr) | 1970-07-17 | 1971-12-24 | Rhone Poulenc Sa | Nouveaux dérivés de la thiazolidine, leur préparation et les compositions qui les contiennent. |
AU646464B2 (en) | 1990-04-27 | 1994-02-24 | Orion-Yhtyma Oy | New pharmacologically active catechol derivatives |
TW221689B (ko) | 1991-08-27 | 1994-03-11 | Otsuka Pharma Co Ltd | |
DK0638075T3 (da) | 1993-02-26 | 2002-02-18 | Otsuka Pharma Co Ltd | Thiazol- eller imidazolderivater som Maillard-reaktionsinhibitorer |
KR960022486A (ko) * | 1994-12-29 | 1996-07-18 | 김준웅 | 신규 티아졸리딘-4-온 유도체 |
US6353006B1 (en) | 1999-01-14 | 2002-03-05 | Bayer Corporation | Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents |
PT1142885E (pt) | 1999-11-12 | 2007-02-28 | Fujimoto Brothers Co Ltd | Derivados de 2-(n-cianoimino)tiazolidin-4-ona |
US20050019825A9 (en) * | 2002-03-15 | 2005-01-27 | Qing Dong | Common ligand mimics: pseudothiohydantoins |
EA011807B1 (ru) | 2002-07-10 | 2009-06-30 | Лаборатуар Сероно Са | Азолидинонвинильные производные конденсированного бензола |
GB0217152D0 (en) | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
AU2003261434A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Iminothiazolidinones as inhibitors of hcv replication |
DK1567112T3 (da) | 2002-11-22 | 2009-02-09 | Smithkline Beecham Corp | Thiazolidin-4-oner til at hæmme hYAK3-proteiner |
US20040167192A1 (en) * | 2003-01-16 | 2004-08-26 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
RU2379299C2 (ru) | 2003-11-21 | 2010-01-20 | Актелион Фармасьютиклз Лтд | Производные 5-(бенз-(z)-илиден)тиазолидин-4-она и их применение в качестве иммуносупрессорных агентов |
USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
JP2007523957A (ja) | 2004-02-25 | 2007-08-23 | スミスクライン・ビーチャム・コーポレイション | 新規化学化合物 |
WO2006094233A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N,n'-dicyclic isothiourea sirtuin modulators |
US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
EP2489662B1 (en) | 2006-11-23 | 2014-08-06 | Actelion Pharmaceuticals Ltd. | Intermediates of a new process for the preparation of 5-benzylidene-2-alkylimino-3-phenylthiazolidin-4-one derivatives |
BRPI0909625B1 (pt) | 2008-03-17 | 2021-09-08 | Actelion Pharmaceuticals Ltd | Agonista seletivo do receptor s1p1 para o uso como um medicamento, uso de um agonista seletivo do receptor s1p1 e kit contendo diferentes unidades de medicação de um agonista seletivo do receptor s1p1 |
GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
-
2004
- 2004-11-16 RU RU2006121651/04A patent/RU2379299C2/ru active
- 2004-11-16 JP JP2006540283A patent/JP4061332B2/ja active Active
- 2004-11-16 WO PCT/EP2004/012953 patent/WO2005054215A1/en active Application Filing
- 2004-11-16 BR BRPI0416752A patent/BRPI0416752B8/pt active IP Right Grant
- 2004-11-16 KR KR1020067009783A patent/KR100783835B1/ko active IP Right Grant
- 2004-11-16 NZ NZ547962A patent/NZ547962A/en unknown
- 2004-11-16 US US13/194,172 patent/USRE43728E1/en active Active
- 2004-11-16 PT PT04819591T patent/PT1689726E/pt unknown
- 2004-11-16 US US10/580,169 patent/US7435828B2/en not_active Ceased
- 2004-11-16 CA CA2545582A patent/CA2545582C/en active Active
- 2004-11-16 CN CNB2004800342094A patent/CN100567275C/zh active Active
- 2004-11-16 EP EP10007267A patent/EP2295418A1/en not_active Withdrawn
- 2004-11-16 AT AT04819591T patent/ATE483698T1/de active
- 2004-11-16 AU AU2004295047A patent/AU2004295047B2/en active Active
- 2004-11-16 ES ES04819591T patent/ES2352555T3/es active Active
- 2004-11-16 DK DK04819591.1T patent/DK1689726T3/da active
- 2004-11-16 SI SI200431556T patent/SI1689726T1/sl unknown
- 2004-11-16 PL PL04819591T patent/PL1689726T3/pl unknown
- 2004-11-16 EP EP04819591A patent/EP1689726B1/en active Active
- 2004-11-16 DE DE602004029493T patent/DE602004029493D1/de active Active
- 2004-11-19 MY MYPI20044811A patent/MY145074A/en unknown
- 2004-11-19 TW TW093135720A patent/TWI323659B/zh active
- 2004-11-19 AR ARP040104281A patent/AR047128A1/es active IP Right Grant
-
2006
- 2006-05-18 IL IL175758A patent/IL175758A/en active IP Right Grant
- 2006-05-30 NO NO20062483A patent/NO336734B1/no unknown
- 2006-06-20 ZA ZA200605077A patent/ZA200605077B/en unknown
-
2007
- 2007-10-26 JP JP2007279142A patent/JP4129286B2/ja active Active
-
2008
- 2008-02-05 US US12/026,277 patent/US7626037B2/en not_active Ceased
- 2008-06-03 US US12/132,443 patent/US7875726B2/en not_active Ceased
-
2009
- 2009-07-02 US US12/496,945 patent/US8273779B2/en active Active
-
2010
- 2010-12-10 CY CY20101101140T patent/CY1111087T1/el unknown
- 2010-12-21 HR HR20100714T patent/HRP20100714T1/hr unknown
-
2012
- 2012-08-09 US US13/570,956 patent/US8524752B2/en active Active
-
2013
- 2013-07-26 US US13/951,954 patent/US9000018B2/en active Active
- 2013-09-17 US US14/028,712 patent/USRE45174E1/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1219612A1 (en) * | 1999-09-14 | 2002-07-03 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
Non-Patent Citations (1)
Title |
---|
JOURNAL OF BIOLOGICAL CHEMISTRY, vol.277, no.40, pp37235-37241 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101409597B1 (ko) * | 2008-10-20 | 2014-06-20 | 액테리온 파마슈티칼 리미티드 | (r)-5-[3-클로로-4-(2,3-디하이드록시-프로폭시)-벤즈[z]일리덴]-2-([z]-프로필이미노)-3-0-톨릴-티아졸리딘-4-온의 결정 형태 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100783835B1 (ko) | 면역억제제로서 5-(벤즈-(z)-일리덴-티아졸리딘-4-원유도체 | |
USRE43833E1 (en) | Thiazolidin-4-one derivatives | |
JP2703408B2 (ja) | 1,4‐ベンゾチアゼピン誘導体 | |
EP1991536A2 (en) | Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome | |
ZA200700535B (en) | 1, 1a, 5, 5a-tetrahydro-3-thia-cyclopropa[a]pentalenes: tricyclic thiophene derivatives as s1p1/edg1 receptor agonists | |
EP3441389B1 (en) | Pyrazole-oxazolidinone compound for anti-hepatitis b virus | |
EP3508483B1 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
JP2004107220A (ja) | TNF−α産生抑制剤 | |
FR2796380A1 (fr) | Nouveaux derives d'aminothiazoles, leur preparation et les compositions pharmaceutiques les contenant | |
MXPA06005590A (en) | 5-(benz- (z) -ylidene) -thiazolidin-4-one derivatives as immunosuppressant agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121123 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20131122 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20141125 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20151120 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161129 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20171124 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20181126 Year of fee payment: 12 |